SFA Therapeutics

11:15 AM - 11:30 AM, Tuesday, June 4,2019 ・ Theater 4
SFA Therapeutics is a development-stage bio-pharmaceutical startup company focused on a new advancement in the treatment inflammatory diseases, targeting NF-Kb. Chronic inflammation has been implicated in a wide range of diseases, including rheumatoid arthritis, psoriatic arthritis, lupus (SLE), inflammatory bowel disease (IBD), Crohn's Disease, Psoriasis, Liver Disease and even certain forms of cancer. Our small-molecule drugs are derived from natural substances identified at Temple University and enable a new platform for developing treatments potentially aimed at over 65 inflammatory diseases currently afflicting patients; with safer treatments than current therapies. Our initial focus is in Psoriasis and Liver Disease (Hepatitis B, NASH and HCC). Patents have been filed in both diseases, based on animal data in Liver Disease and on a small human trial in Psoriasis.
Speaker
photo
CEO
SFA Therapeutics